Inhibition of Epithelial–Mesenchymal Transition and Migration in Cisplatin-resistant Cancer Through Combined Treatment With Cisplatin and SH003
Combining cisplatin and SH003 therapy may potentially be a more effective strategy for treating cisplatin-resistant cancer by increasing cytotoxicity and inhibiting metastasis. Further research is required to elucidate the underlying mechanisms and evaluate the in vivo efficacy of this combination therapy.
Authors
- J.H. Ku
- Pil‐Young Yun (ORCID: https://orcid.org/0000-0001-6097-1229)
- Seong‐Gyu Ko (ORCID: https://orcid.org/0000-0002-2345-430X)
- Hyeong Sim Choi
Institutions
- Seoul National University (KR)
- Seoul National University Bundang Hospital (KR)
- Kyung Hee University (KR)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-09-30
- DOI
- https://doi.org/10.21873/anticanres.17265
- Citations
- 1
- Primary Topic
- RNA Research and Splicing
- Type
- article
- Field-Weighted Citation Impact
- 0.23